Advertisement

Current Medical Science

, Volume 37, Issue 6, pp 943–947 | Cite as

Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study

  • Fang Xie (解 方)
  • Rui Wang (王 睿)
  • Zi-gang Zhao (赵梓纲)
  • Xian-fu Meng (孟宪芙)
  • Bi-wen Lin (林碧雯)
  • Jie Yang (杨 洁)
  • Wen-juan Wang (王文娟)
  • Xiang-yu Ding (丁香玉)
  • Yi Yang (杨 怡)
  • Hua Zhao (赵 华)
  • Cheng-xin Li (李承新)
  • Heng-jin Li (李恒进)
  • Yong Zhou (周 勇)Email author
Article

Summary

Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates (PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate- to-severe plaque psoriasis.

Key words

efficacy plaque psoriasis etanercept 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol, 2010,146(1):46–54CrossRefPubMedGoogle Scholar
  2. 2.
    Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet, 2007,370(9583):263–271CrossRefPubMedGoogle Scholar
  3. 3.
    Liu XX, Feng AP, He YM, et al. Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis. J Huazhong Univ Sci Technol [Med Sci], 2016,36(1):132–136CrossRefGoogle Scholar
  4. 4.
    Busard C, Zweegers J, Limpens J, et al. Combined use of systemic agents for psoriasis: a systematic review. JAMA Dermatol, 2014,150(11):1213–1220CrossRefPubMedGoogle Scholar
  5. 5.
    Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol, 2007,25(6):574–580CrossRefPubMedGoogle Scholar
  6. 6.
    Lima XT, Oliveira RT, Braga FG, et al. Circulating levels of chemokines in psoriasis. Autoimmunity, 2015,48(1):57–60CrossRefPubMedGoogle Scholar
  7. 7.
    Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature, 2007,445(7128):648–651CrossRefPubMedGoogle Scholar
  8. 8.
    Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol, 2009,129(1):79–88CrossRefPubMedGoogle Scholar
  9. 9.
    Antiga E, Volpi W, Cardilicchia E, et al. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol, 2012,32(6):1221–1232CrossRefPubMedGoogle Scholar
  10. 10.
    Tonel G, Conrad C, Laggner U, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol, 2010,185(10):5688–5691CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Witte E, Kokolakis G, Witte K, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol, 2014,134(11):2757–2767CrossRefPubMedGoogle Scholar
  12. 12.
    Schotte H, Schluter B, Willeke P, et al. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology, 2004,43(8):960–964CrossRefPubMedGoogle Scholar
  13. 13.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003,349(21):2014–2022CrossRefPubMedGoogle Scholar
  14. 14.
    Puig L, Camacho Martinez FM, Gimeno Carpio E, et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology, 2012,225(3):220–230CrossRefPubMedGoogle Scholar
  15. 15.
    Maria Fernandez-Torres R, Paradela S, Fonseca E. Long-term efficacy of etanercept for plaque-type psoriasis and estimated cost in daily clinical practice. Value Health, 2015,18(8):1158–1161CrossRefPubMedGoogle Scholar
  16. 16.
    Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics, 2014,8:169–182PubMedPubMedCentralGoogle Scholar
  17. 17.
    Tsai YC, Tsai TF. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol, 2016,151(4):412–431PubMedGoogle Scholar
  18. 18.
    Chiu HY, Wang TS, Cho YT, et al. Etanercept use for psoriasis in Taiwan: a case series study. Int J Dermatol, 2013,52(6):673–680CrossRefPubMedGoogle Scholar
  19. 19.
    Wu YF SY, Yang CH, Huang YH. Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. Dermatol Sin, 2013,31:49–53CrossRefGoogle Scholar
  20. 20.
    Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica, 1978,157(4):238–244CrossRefPubMedGoogle Scholar
  21. 21.
    Campa M, Mansouri B, Warren R, et al. A Review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther, 2016,6(1):1–12CrossRefGoogle Scholar
  22. 22.
    Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med, 1999,130(6):478–486PubMedGoogle Scholar
  23. 23.
    Nast A, Jacobs A, Rosumeck S, et al. Efficacy and safety of systemic long-term treatments for moderateto-severe psoriasis: A systematic review and meta-analysis. J Invest Dermatol, 2015,135(11):2641–2648CrossRefPubMedGoogle Scholar
  24. 24.
    Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderateto-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet, 2015,386(9993):541–551CrossRefPubMedGoogle Scholar
  25. 25.
    Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol, 2016,74(2):280–287CrossRefPubMedGoogle Scholar
  26. 26.
    Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol, 2006,54(3 Suppl 2):S92–100CrossRefPubMedGoogle Scholar
  27. 27.
    Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 2005,152(6):1304–1312.CrossRefPubMedGoogle Scholar
  28. 28.
    Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat, 2013,24(3):169–178CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology 2017

Authors and Affiliations

  • Fang Xie (解 方)
    • 1
  • Rui Wang (王 睿)
    • 1
  • Zi-gang Zhao (赵梓纲)
    • 1
  • Xian-fu Meng (孟宪芙)
    • 1
  • Bi-wen Lin (林碧雯)
    • 1
  • Jie Yang (杨 洁)
    • 2
  • Wen-juan Wang (王文娟)
    • 1
  • Xiang-yu Ding (丁香玉)
    • 1
  • Yi Yang (杨 怡)
    • 1
  • Hua Zhao (赵 华)
    • 1
  • Cheng-xin Li (李承新)
    • 1
  • Heng-jin Li (李恒进)
    • 1
  • Yong Zhou (周 勇)
    • 1
    Email author
  1. 1.Department of DermatologyChinese PLA General Hospital, Medical College of Chinese PLABeijingChina
  2. 2.Department of DermatologyAffiliated Hospital of Hebei United University, Medical College of Chinese PLATangshanChina

Personalised recommendations